Zachary Perez (CTR)

Zachary Perez serves as a contracting professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic procurement of critical scientific and diagnostic capabilities. He manages a portfolio of acquisitions focused on laboratory instrumentation, biomedical research services, and data-driven public health systems, ensuring timely access to technologies that enhance infectious disease detection and laboratory capacity. His work directly enables CDC’s rapid response operations by facilitating the acquisition of high-complexity analytical tools and research support services aligned with national health security priorities. Perez maintains consistent working relationships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, New York City Health & Hospitals Corp, MRIGLOBAL, and Cepheid. These partnerships reflect a preference for established industry leaders with proven expertise in diagnostic systems, clinical research infrastructure, and large-scale public health implementation. His contracting approach emphasizes performance-based outcomes, technical compliance, and mission-critical delivery, often involving complex solicitations requiring rigorous scientific and regulatory alignment. Perez’s procurement activity is exclusively conducted under full and open competition, with no set-asides designated for 8(a), HUBZone, SDVOSB, or other socioeconomic programs. This reflects a strategic alignment with CDC’s need for specialized, high-capacity vendors capable of delivering mission-critical capabilities at scale, prioritizing technical capability and operational readiness over socioeconomic preferences. His primary procurement focus lies in NAICS 334516 (Analytical Laboratory Instrument Manufacturing), where he sources advanced diagnostic equipment such as PCR platforms and molecular detection systems. He also frequently procures research and development services under NAICS 541715, supporting epidemiological modeling and life sciences innovation. His domain expertise centers on laboratory automation, clinical diagnostics, and public health data infrastructure, ensuring acquisitions meet stringent federal biosafety and regulatory standards.